Document Detail

Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model.
MedLine Citation:
PMID:  21307819     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The paucity of data on fetal effects of prenatal exposure to chemotherapy prompted us to study the transplacental transport of commonly used anticancer agents in a pregnant baboon model.
METHODS: Single or combination chemotherapy with paclitaxel, docetaxel, carboplatin, and trastuzumab was administered to 9 baboons at a mean (SD) gestational age of 117 (26) days (paclitaxel, 100 mg/m2 [n = 2]; docetaxel, 100 mg/m2 [n = 2]; paclitaxel, 175 mg/m2 with carboplatin, area under the curve of 6 at standard dosage [n = 2] and 50% dosage [n = 1]; docetaxel, 75 mg/m2 with carboplatin, area under the curve 6 [n = 1]; and docetaxel, 75 mg/m2 with trastuzumab, 8 mg/kg [n = 1]). Serial fetal and maternal blood samples, amniotic fluid, maternal urine, and fetal and maternal tissue samples were collected for the first 76 hours after drug infusion. Levels of carboplatin were determined by atomic absorption spectrometry, docetaxel and paclitaxel by high-performance liquid chromatography, and trastuzumab by enzyme-linked immunosorbent assay.
RESULTS: Fetal plasma concentrations of carboplatin averaged 57.5% (14.2%) of maternal concentrations (n = 7). Fetal plasma concentrations were 1.5% (0.8%) of maternal concentrations (n = 7). Immediately after ending the infusion, paclitaxel was not detectable in fetal tissues, whereas, after 3 hours, fetal tissues contained 15% of maternal tissue concentrations.Docetaxel could not be detected in fetal blood samples (n = 9). In the first 3 hours after docetaxel infusion, fetal tissues contained 5.0% to 50.0% of maternal tissue concentrations, whereas equal fetal and maternal tissue concentrations were found after 26 and 76 hours.The transplacental passages of trastuzumab were 85.0% and 3.0%, 2 and 26 hours after trastuzumab infusion, respectively. After 26 hours, amniotic fluid contained 36.4% of the fetal plasma concentration. Fetal tissue concentrations varied between 5.0% and 14.0% of the maternal concentration.
CONCLUSION: Variable plasma and/or tissue concentrations of taxanes, carboplatin, and trastuzumab were encountered in the fetal compartment. These data are important when cancer treatment is considered during pregnancy and underline the need for long-term follow-up of children after prenatal exposure to these cytotoxic agents.
Kristel Van Calsteren; Rene Verbesselt; Roland Devlieger; Luc De Catte; Daniel C Chai; Rieta Van Bree; Liesbeth Heyns; Jos Beijnen; Sonia Demarsin; Ernst de Bruijn; Jan de Hoon; Frédéric Amant
Related Documents :
8408499 - Immunolocalization of oestrogen and progesterone receptors in the human decidua in rela...
24521459 - Benefits of repeated individual dietary counselling in long-term weight control in wome...
21273359 - Prescribing in pregnancy and during breast feeding: using principles in clinical practice.
21516919 - Factors related to dimensions of grief intensity among african-american women after pre...
3859989 - Studies on the mechanism of action of antifertile pg in animal models.
2664619 - Adenomyosis: current perspectives.
19517699 - Uterine torsion in delayed diagnosis of abnormal anterior placentation: a report of 2 c...
19412349 - Maternal circulating levels of activin a, inhibin a, sflt-1 and endoglin at parturition...
1572069 - The development of cholecystokinin in the interpeduncular nucleus of rats.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society     Volume:  20     ISSN:  1525-1438     ISO Abbreviation:  Int. J. Gynecol. Cancer     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2011-02-10     Completed Date:  2011-06-02     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9111626     Medline TA:  Int J Gynecol Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1456-64     Citation Subset:  IM    
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / pharmacokinetics
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / pharmacokinetics*
Biological Transport / physiology
Carboplatin / pharmacokinetics
Gestational Age
Maternal-Fetal Exchange / drug effects
Models, Animal*
Paclitaxel / pharmacokinetics
Placenta / drug effects,  metabolism*
Pregnancy, Animal* / metabolism
Taxoids / pharmacokinetics
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/Taxoids; 15H5577CQD/docetaxel; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High rate of coronary artery abnormalities in adolescents and young adults infected with human immun...
Next Document:  A Convenient and Safe O-Methylation of Flavonoids with Dimethyl Carbonate (DMC).